steroids. 1 The challenge in treating CAH is to provide sufficient cortisol replacement to suppress overproduction of adrenal androgens (hyperandrogenaemia) while avoiding the effects of cortisol excess (hypercortisolaemia). Adding to the challenge is HC's short median elimination half-life in CAH children, 58 minutes (range: 41-105 minutes), allowing most of the HC dose to be eliminated from the body within 4-5 hours.
2 Because of HC's short half-life, the recommended 3 times a day dosing schedule exposes children to alternating periods of hypo-and hypercortisolaemia with resultant hyperandrogenemia throughout each day.
Evidence for the effects of increased adrenal sex steroids in CAH and glucocorticoid therapy on bone mineral density (BMD) are mixed, with some studies finding no difference in BMD between children with CAH and controls, [3] [4] [5] [6] [7] [8] others finding lower BMD in children with CAH, [9] [10] [11] [12] [13] [14] [15] and one study finding increased BMD. 16 While androgens have an established positive effect on BMD through stimulation of osteoblastic activity, 17 glucocorticoids can have an opposite detrimental effect. Glucocorticoids reduce BMD through several mechanisms including decreasing osteoblastic activity, decreasing calcium absorption in the gastrointestinal tract, enhancing renal losses of calcium and increasing bone resorption. 18 The effects of adrenal sex steroids and glucocorticoids on measures of body composition, such as visceral adipose tissue (VAT) and the Android:Gynoid (A:G) ratio, have not been well studied in children with CAH. This area of investigation is important given that children and adults with CAH may have higher risk for cardiovascular disease compared to the general population. 19 VAT is associated with increased cardiometabolic risk, 20 while the A:G ratio is associated with elevated triglyceride levels and lower HDL levels and is a better predictor of cardiovascular risk than BMI. 21 Although the A:G ratio can be calculated from dual-energy X-ray absorptiometry (DXA) measures, 22 data quantitating VAT in children with CAH are limited, and no studies have examined VAT using DXA. Estimation of abdominal VAT using DXA has been validated in adults, 23 and DXA has been shown to provide a reliable estimate in children as well. 22 The aims of this study were to: (i) compare BMD in children with CAH to healthy controls; (ii) compare VAT and the A:G ratio in children with CAH to healthy controls; and (iii) determine the relationship between BMD and VAT in children with CAH and in healthy controls. 
| ME THODS

| Subjects
| Anthropometrics
Each case and control underwent height and weight measurements and a DXA scan as part of either clinical (cases) or research (controls) protocols. For controls, height and weight measurements were taken three times on the day of the DXA examination on a calibrated, wall-mounted stadiometer and averaged. For cases, height and weight measurements were obtained in a similar fashion from the closest clinic visit to the DXA examination (average 9 days from the DXA examination). Height and weight Z-scores were calculated using GenenCALC 3.0 Software. BMI Z-scores were generated for all cases and controls using standard growth charts from the Center for Disease Control (CDC). 24 Tanner staging of puberty was assessed either at the closest clinic visit to the DXA examination or on the day of the DXA examination (controls). Breast development was assessed in both female cases and controls. For males, testicular volume was measured in cases only, with a volume of 4 cc or greater being considered pubertal. Pubic hair was assessed in male cases and controls and female cases.
| DXA
Dual-energy X-ray absorptiometry scans for both cases and controls were performed using GE Lunar iDXA system (iDXA, General
Electric Medical Systems, Madison, WI, USA). Total body bone mineral density (TBMD) Z-scores were calculated using pediatric software, and TBMD Z-scores were adjusted for height-for-age Z-scores (TBMD HAZ ) applying the method of Zemel, et al, 25 to this study's control subjects. Total body composition measures (per cent total tissue fat, android fat mass and gynoid fat mass) were calculated from DXA using enCore™ software (platform version 16.3, General
Electric Medical Systems, Madison, WI, USA). Estimates of abdominal visceral adipose tissue (VAT) were obtained using methods previously described for children and adolescents. 23 Android (abdominal) fat was measured using a region-of-interest automatically defined with a caudal limit placed at the top of the iliac crest and its height set to twenty per cent of the distance from the top of the iliac crest to the base of the skull. 26 The gynoid region (hip/gluteal) is located mid-pelvis to mid-thigh, with the upper limit set below the iliac crest a distance 1.5 times the height of the android region and the lower limit set a distance of 2 times the height of the android region. 26 All scans were reviewed for accurate placement of the android box. By default, a VAT value of 2 grams or less was outside the precision of the machine and considered to be inaccurate, either because the value was below the threshold to detect VAT or the DXA machine could not accurately measure the VAT. Only one case and 5 controls had a VAT value of 2 grams or less; these values were removed from analyses.
| Glucocorticoids
Most cases with CAH were being treated with HC (79%). There were 2 cases on prednisone and 3 cases on dexamethasone who had transitioned from HC after reaching their final adult heights. Five cases with nonclassic CAH were not on treatment with glucocorticoids but still had evidence of hyperandrogenemia with advanced bone age and/or growth acceleration. Prednisone and dexamethasone doses were converted to equivalent HC doses in mg/m 2 /d using standard glucocorticoid equivalencies (20 mg of HC = 5 mg of prednisone = 0.4 mg of dexamethasone). 27 For each case, the mean HC dose was calculated from treatment doses recorded at available clinic visits performed within 3, 6 and 12 months prior the DXA examination (mean number of clinic visits was 2.8).
| Bone age
A bone age radiograph was performed only in cases with CAH, and bone age Z-scores were used as a surrogate measure of androgen exposure. The bone age radiograph closest in time to the DXA scan (median 3 months) was interpreted using the Greulich and Pyle method. Bone age Z-scores for cases were calculated using the fol- TA B L E 1 Characteristics of CAH cases and controls chronological age). 28 Bone age means and standard deviations for girls and boys were obtained from Greulich and Pyle.
| Statistical analysis
Preliminary analyses showed that the distribution of VAT Mass was skewed to the right (ie had a long upper tail) so it was more appropriate to the use the common log (log to base 10) of VAT Mass Analyses that included cases only used one-way ANOVA or multiple linear regression and the closely associated Pearson's correlation (r).
All analyses were performed using JMP (v. 12.0 Pro, SAS Institute Inc, Cary, NC). 
| RE SULTS
| BMD
Cases had lower TBMD Z-scores compared to controls (0.81 vs 1.27, P = .003) ( Table 2) . This difference remained significant after adjusting for height-for-age Z-scores (ie Zemel adjustment, −0.51 vs −0.01, P = .001). TBMD Z-scores were positively correlated with bone age Z-scores in cases with CAH (r = .63, P < .0001), even after adjusting for height-for-age Z-scores (r = .51, P = .001) (Figure 1 ). TBMD
and TBMD HAZ Z-scores were not associated with average HC dose (P = .68 and P = .67, respectively), CAH subtype (P = .22 and P = .50, respectively) or age at diagnosis (P = .18 and P = .23, respectively).
| Body composition
Visceral adipose tissue did not differ significantly between cases and controls (adjusted average log 10 VAT Mass 2.00 vs 2.11, P = .11) (Table 2) . Adjusting VAT for height SD, age and sex had negligible effects on this comparison; VAT still did not differ between cases and controls after adjustment (P = .16). Among CAH cases, the association between VAT and bone age Z-scores trended in the negative direction (r = −.26) but did not reach significance (P = .11). VAT was not significantly associated with HC dose (P = .98), CAH subtype (P = .36) or age at diagnosis (P = .15 Written as adjusted average (standard error); CAH, congenital adrenal hyperplasia; BMD, bone mineral density; TBMD, total body bone mineral density; TBMD HAZ , total body bone mineral density Zscores adjusted for height-for-age Z-scores; VAT, visceral adipose tissue; A:G, Android:Gynoid ratio. *Indicates a significant value.
TA B L E 2 CAH cases and controls compared according to BMD and body composition measures F I G U R E 1 Correlation plots between total bone mineral density (TBMD) Z-scores and bone age Z-scores (left) and TMBD Z-scores adjusted for height-forage Z-scores (TBMD HAZ ) and bone age Z-scores (right) for CAH cases controls, P = .052) and A:G ratios (0.405 in cases vs 0.411 in controls, P = .33) than controls, the differences did not reach significance. The A:G ratio was not associated with average HC dose (P = .08), CAH subtype (P = .29) or age at diagnosis (P = .33).
| BMD vs VAT
In CAH cases, TBMD and TBMD HAZ Z-scores and log 10 VAT were negatively correlated after adjusting for BMI Z-score (for TBMD, slope = −0.66, P = .024; for TBMD HAZ, slope = −0.96, P =<.001).
The correlation between TBMD HAZ Z-scores and VAT remained upon further adjustment for bone age Z-score (for TBMD, P = .30;
for TBMD HAZ, P < .001). VAT was not associated with TBMD or TBMD HAZ Z-scores in controls after adjustment for BMI Z-score (for TBMD, slope = −0.005, P = .98; for TBMD HAZ, slope = −0.17, P = .38).
| D ISCUSS I ON
We found that children with CAH had lower TBMD Z-scores compared to controls, with the difference being about the same with or without adjustment for height-for-age. TBMD and TBMD HAZ Z-scores were positively correlated with bone age Z-scores but were not associated with HC dose, CAH subtype or age at diagnosis. Among studies that reported decreased BMD in CAH children compared to controls, two studies found that higher HC dose (or its equivalents) was associated with lower BMD Z-scores, 12,14 whereas
Demirel et al 15 and our study found no association. The rest of the studies did not examine this relationship. 9, 10, 13 Most children in the two studies that found a negative relationship were on long-acting glucocorticoids. The finding of no relationship between total daily HC dose and decreased BMD suggests that other factors such as dose distribution, individual cortisol pharmacokinetics, glucocorticoid receptor sensitivity and type of glucocorticoid, all of which determine cortisol and androgen exposures over the course of the day, may play a role in the impact of glucocorticoids on BMD. For example, in our study, patients were treated with HC within the recommended range, but this did not prevent the presumed adverse effects of glucocorticoids on BMD as potentially some patients were more glucocorticoid sensitive or had decreased cortisol clearance and/or increased half-life, and therefore had higher biologically active glucocorticoid available at the tissue level.
Among studies that reported decreased BMD, the relationship between advanced bone age and BMD Z-scores was examined only in de Almeida Freire et al 10 , who found, as we did, that in CAH cases, advanced bone age was associated with higher BMD Z-scores. This finding is not surprising as higher bone age Z-scores indicate greater androgen exposure which can lead to an increase in BMD through androgen stimulation of osteoblastic activity. 17 Aromatization of elevated adrenal androgen to oestrogen may also have some protective effects on bone. Oestrogen reduces the release of inflammatory cytokines such as IL-6, IL-1 and TNF-alpha from osteoblasts and decreases osteoclastic activity by suppressing RANK-L-induced osteoclast differentiation. 29 In addition, oestrogen can increase osteoprotegerin production 30 and prevent glucocorticoid-induced apoptosis in osteoblasts. 31 Several studies have found no difference in BMD Z-scores between children with CAH and controls. [3] [4] [5] [6] [7] [8] 11 In some of these studies, national reference data were used instead of age-matched, sexmatched and BMI-matched controls 3,4,7,11 ; BMD was not adjusted for height-for-age Z-score, 4-8 which could lead to underestimation or overestimation of BMD Z-score 25 ; the CAH subtype 3, 4 or the type of glucocorticoid was not always specified 4, 7 ; and in one study, only females with CAH were evaluated. 8 Three of these studies found no association between HC dose and BMDZ-scores, 4, 8, 11 and the rest did not examine the relationship. 3, [5] [6] [7] Only one study found increased BMD in children with CAH,
16
but that study differed from ours in that it included not only children with 21-hydroxylase deficiency but also 11β-hydroxylase deficiency;
did not use age-matched, sex-matched and BMI-matched controls;
did not adjust BMD Z-scores for height-for-age Z-scores; did not examine measures of androgen control; did not specify the type of glucocorticoid used; and did not specify the pubertal status of the patients.
Our study was the first to use DXA to calculate VAT in children with CAH and found no difference in VAT between cases and controls. Only one previous study, by Kim et al, 32 quantitated VAT in children with CAH using a computed tomography scan and found in- VAT specifically, inhibits lipoprotein lipase (which promotes fat accumulation). 34 While we did not find a significant negative association between bone age Z-scores and VAT, the association trended in this direction, which may imply that increased adrenal sex steroids have a role in decreasing VAT in children with CAH.
We found a negative correlation between VAT and TBMD and TBMD HAZ Z-scores in the CAH cases, but did not find this association in controls. Adipose tissue secretes various inflammatory cytokines, such as TNF-a and IL-6, which enhance osteoclast differentiation and activation and inhibit osteoclast apoptosis. 35 Altered hypothalamic-pituitary-adrenal axis and chronic fluctuations of cortisol and adrenal sex steroids may affect fat distribution and may increase secretion of inflammatory cytokines from VAT, leading to the inverse relationship between VAT and bone mineral density. 35 The strengths of our study were the use of age-matched, sexmatched and BMI-matched controls; adjustment of BMD Z-scores for height-for-age Z-scores given that CAH patients tend to be taller than their peers during childhood; having most of our subjects on HC; and use of bone age Z-scores to assess chronic androgen exposure rather than single measures of steroid concentrations which reflect control only at the time of measurement. Limitations of our study include its retrospective design as well as not having the testicular examination or bone age performed in controls. Cumulative glucocorticoid dosing since birth was not calculated as this information was not available in all patients. However, we examined the effect of age at diagnosis on BMD as an indirect measure of duration of glucocorticoid exposure and found no relationship between BMD and age at diagnosis. In conclusion, we found that CAH cases had lower TBMD than controls and that VAT and BMD were nega- 
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